Aspira Women's Health, Inc. (AWH)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Aspira Women's Health, Inc. (AWH)
Company Performance

Current Price

as of Oct 18, 2024

$0.87

P/E Ratio

N/A

Market Cap

$13.97M

Description

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Metrics

Overview

  • HQAustin, TX
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerAWH
  • Price$0.87+2.03%

Trading Information

  • Market Cap$13.97M
  • Float68.91%
  • Average Daily Volume (1m)63,263
  • Average Daily Volume (3m)76,783
  • EPS-$1.45

Company

  • Revenue$8.92M
  • Rev Growth (1yr)-2.73%
  • Net Income-$3.53M
  • Gross Margin58.65%
  • EBITDA Margin-180.23%
  • EBITDA-$4.37M
  • EV$20.05M
  • EV/Revenue2.25
  • P/EN/A
  • P/S1.22
  • P/BN/A
Documents
SEC Filings
8-K (2024-10-18)
8-K (2024-09-13)
8-K (2024-08-12)
8-K (2024-08-02)
8-K (2024-07-31)
8-K (2024-07-29)
8-K (2024-07-05)
8-K (2024-07-02)
8-K (2024-06-27)
8-K (2024-06-14)
8-K (2024-06-07)
8-K (2024-05-15)
8-K (2024-05-14)
8-K (2024-04-26)
8-K (2024-03-28)
8-K (2024-03-25)
8-K (2024-03-21)
8-K (2024-01-25)
8-K (2024-01-05)
8-K (2023-12-27)
8-K (2023-12-06)
8-K (2023-11-13)
8-K (2023-10-23)
8-K (2023-10-13)
8-K (2023-09-13)
8-K (2023-09-12)
8-K (2023-08-14)
8-K (2023-08-09)
8-K (2023-07-24)
8-K (2023-07-20)
8-K (2023-07-14)
8-K (2023-06-28)
8-K (2023-06-02)
8-K (2023-05-16)
8-K (2023-05-11)
8-K (2023-05-10)
8-K (2023-04-28)
8-K (2023-03-30)
8-K (2023-03-22)
8-K (2023-03-13)
8-K (2023-03-03)
8-K (2023-03-02)
8-K (2023-02-10)
8-K (2023-02-07)
8-K (2023-01-10)
8-K (2023-01-09)
10-Q (2024-08-13)
10-Q (2024-05-15)
10-Q (2023-11-13)
10-Q (2023-08-14)
10-Q (2023-05-15)
10-K (2024-04-01)
10-K (2023-03-30)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Aspira Women's Health Q3 (2023-11-22T15:41:35Z)
Aspira Women's Health secures reimbursement for Ova1Plus from California Medicaid (Medi-Cal) ($3.33, 0.00) (2023-11-28T13:04:19Z)
Aspira Women's Health reports Q3 EPS ($0.48) vs FactSet ($0.51) [4 est, ($0.67)-(0.43)] ($3.70, 0.00) (2023-11-13T21:09:02Z)
Aspira Women's Health receives final crosswalk pricing determination from CMS for OvaWatch ($3.28, +0.04) (2023-11-27T14:52:56Z)
Aspira Women's Health comments on CMS proposed rule to crosswalk Medicare reimbursement rate for OvaWatch ($4.15, 0.00) (2023-11-09T13:06:17Z)
Aspira Women's Health announces poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research ($5.37, 0.00) (2023-10-25T12:06:05Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-13)
Earnings Report (2023-08-14)
Factset
Factset Business Description